Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.56 |
| ▸ | PPARA | Q07869 | 15/20 | 0.56 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 7/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6819104 | 0.92 | PPARG (0.59) | PPARGPPARAPTGESALOX5PPARD | |
| SCHEMBL6815781 | 0.91 | PPARA (0.69) | PPARGPPARAPTGESALOX5PPARD | |
| SCHEMBL6822804 | 0.85 | PPARG (0.59) | PPARGPPARAPTGESALOX5PPARD | |
| SCHEMBL6819715 | 0.85 | PPARG (0.59) | PPARGPPARAPTGESALOX5PPARD | |
| SCHEMBL6819587 | 0.85 | PPARG (0.59) | PPARGPPARAPTGESALOX5PPARD | |
| SCHEMBL6819926 | 0.84 | PPARG (0.69) | PPARGPPARAPTGESALOX5PPARD | |
| SCHEMBL6818869 | 0.84 | PPARG (0.69) | PPARGPPARAPTGESALOX5PPARD | |
| SCHEMBL6819491 | 0.84 | PPARG (0.69) | PPARGPPARAPTGESALOX5PPARD | |
| SCHEMBL6819532 | 0.77 | PPARG (0.61) | PPARGPPARAPPARDSIGMAR1 | |
| SCHEMBL6819978 | 0.77 | PPARA (0.61) | PPARGPPARAPTGESALOX5PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750252-B2 | FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | claimed |
| EP-1237856-B1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2004-05-12 | — | — | EP | claimed |
| WO-2004087643-A1 | DEFORMYLASE INHIBITOR, PROCESS FOR PREPARING THE SAME, AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME | PROMEDITECH INC. (KR) | 2004-10-14 | — | — | WO | disclosed |
| US-6750252-B2 | FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1237856-B1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | GPR119, IAPP, INSR | PPARG 46/4885PPARA 87/4885PTGES 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.